The photos in this paper contain many unexpected repetitive features, both within as well as between the panels. This appeared to be a severe case of photographic editing. So I reported this paper to the journal and the university.
Unfortunately, the University of Illinois just let me know that they will not investigate this case – because it is too old.
“Are you looking to buy your own custom-made scientific paper? You have come to the right place. We are the Stock Photo Paper Mill! You can pick and choose all kinds of great items from our pool of stock photos to create your own paper. We have photos featuring colony formation, wound healing, and transwell assays. We have survival plots and flow cytometry panels too! Just pick what you like from our catalog, and we will turn your selection into your own, unique paper. “
A hypothetical commercial for a paper mill.
Stock photos are photos that you can pick and buy from a catalog. Some sites even offer free stock photos. Stock photos are often used by new sites and bloggers to illustrate their stories. Some photos can even be funny, especially if they depict models pretending to be professionals. On MicrobiomeDigest.com I have several blog posts about laboratory stock photo fails that might make you smile.
Here I will discuss the Stock Photo Papers, a set of 121 papers, almost exclusively published in the same scientific journal. The papers all have different authors from different institutions, and describe different cancer types and tissue samples.
However, although each of these papers looks unique at first glance, all papers in this set contain images from the same library of about 100 photos and plots. Like images in a stock photo library, each of these photos was used multiple times in different papers. My findings, covered by Eva Xiao in the Wall Street Journal, suggest that they were all created by the same paper mill.
Today I found four papers that appear to share colony formation and tumor photos with each other. Because they do not share authors or institutions, and because they all investigated a different type of cancer, it is hard to imagine how these four ended up with the same photos. The authors might have all used the same outsourcing laboratory or paper mill.
Several people asked me to say something about a rather fantastical finding, that SARS-CoV-2 might already have been lurking in Barcelona sewers in March 2019, a year before the first COVID-19 case was reported in Spain.
It was reported by a group from University of Barcelona and posted as a non-peer reviewed preprint on MedRxiv on June 13.
With fantastic claims should come fantastic data. That is not the case here.
Let’s dive into the Barcelona sewers to find out the details.
Surgisphere is a company that specializes in the analysis of clinical data. It provided the large datasets on COVID-19 patients that formed the basis of two papers recently published in The Lancet and The New England Journal of Medicine, both of which were retracted on June 4th. Suspicions had been raised about the validity of the data, provided by Surgisphere founder Sapan S. Desai (archived ResearchGate page) who was an author on both papers.
But that might not be the only concern about Desai’s work. Here I will discuss a paper from his PhD project at the University of Illinois at Chicago that appears to have some serious image problems.
A follower on Twitter asked me to look at two identical papers. I agreed that they looked very similar, did some searches, and found six more. All eight papers presented the same survival curves, table values, and similar line graphs. But they were published in different journals by different authors, at different institutes, on different patients, and different cancers.
In this blog post, I present to you the Mysterious Case of the Octopaper.
Last week, a new retrospective study from Tongji Hospital in Wuhan was published in Science China Life Sciences (a Springer Link journal). The study found 47% fatalities in critically ill #COVID19 patients that were given regular treatment, and only 19% fatalities in patients treated with low doses of hydroxychloroquine (HCQ).
These results sound amazing.
But I took a closer look. And I have lots of questions.
In the past few years I have found some examples of papers showing photos of mice or rats with very large tumors. Some of these tumors appear to go far beyond what animal ethics guidelines consider to be acceptable.
This post contains images that might be disturbing to some viewers. So, please proceed with caution.
Recently a paper published in Nucleic Acid Therapeutics, a Mary Liebert publication not to be confused with the more glamorous Nucleic Acid Research journal, was brought to my attention. It described the potential use of small RNAs as a therapeutic against SARS-CoV-2.
Alas, it is most memorable because of the alarmingly short time-to-acceptance, lack of references, and the omission of several conflicts of interest.
A new study from Brazil is reporting significant positive effects of hydroxychloroquine (HCQ) + azithromycin (AZM) on early-stage suspected COVID19 cases. The study was posted as a preliminary manuscript draft on Dropbox a couple of days ago. I just tweeted my thoughts in a long thread, but here is a bit more polished version.